Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
GLP-1RAs and dual incretin agonists have been shown to reduce adipocyte hypertrophy and stimulate the activation of BAT, thereby enhancing energy expenditure and metabolic function
You can also apply for manufacturer savings programs to help lower the cost
The round was led by Bain Capital Ventures (BCV) Capital Private Equity, with participation from multiple new and existing investors
However, published data allows a directional comparison of the most common GI events: Adverse Event Retatrutide (12 mg) Semaglutide 2.4 mg (STEP trials) Tirzepatide 15 mg (SURMOUNT trials) Nausea ~46% ~44% ~31% Diarrhea ~33% ~30% ~23% Vomiting ~22% ~24% ~12% Constipation ~17% ~24% ~12% Important caveat: These numbers come from different trial populations and cannot be directly compared
True sustained weight gain affecting more than 5 percent of body weight over 2 to 3 months is less common but documented
Providers may recommend: Treatment decisions should always be individualized
)
